Research programme: mesothelin targeted trispecific killer engager - GT Biopharma
Alternative Names: Mesothelin targeted TriKE - GT Biopharma; MSLN-targeted TriKE - GT BiopharmaLatest Information Update: 24 Mar 2022
At a glance
- Originator GT Biopharma
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 replacements; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer